Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis

Amandeep Godara, Giovanni Palladini

Research output: Contribution to journalReview articlepeer-review


In systemic light-chain amyloidosis, monoclonal antibodies target antigens that are either membrane-bound or circulating or deposited in the organs. CD38 holds high promise as a target against clonal plasma cells. Multiple anti-CD38 antibodies are either approved for use or being investigated in clinical trials. Daratumumab has been investigated and has clinical efficacy in upfront or refractory settings. High rates of hematologic response are seen with daratumumab, which translates to high organ response rates. Rituximab is usually integrated into the treatment regimen for IgM amyloidosis. Anti-amyloid therapies have shown preclinical proof of principle, but lack confirmation of improvement.

Original languageEnglish
JournalHematology/Oncology Clinics of North America
Publication statusAccepted/In press - 2020


  • Anti-amyloid antibodies
  • Daratumumab
  • Elotuzumab
  • Light-Chain amyloidosis
  • Monoclonal antibodies
  • Multiple myeloma
  • Plasma cell
  • Rituximab

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Monoclonal Antibody Therapies in Systemic Light-Chain Amyloidosis'. Together they form a unique fingerprint.

Cite this